Interleukin-10 in cancer immunotherapy: from bench to bedside

Mohamad Adham Salkeni; Aung Naing

doi:10.1016/j.trecan.2023.05.003

Interleukin-10 in cancer immunotherapy: from bench to bedside

Mohamad Adham Salkeni, Aung Naing

Investigational Cancer Therapeutics

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Interleukin (IL)-10 was one of the first cytokines to be recognized. However, its functionality in promoting antitumor immunity was described more recently. Context- and concentration-dependent biological effects are the hallmarks of the pleiotropic role of IL-10. Despite reducing tumor-promoting inflammation, IL-10 may have a role in rejuvenating exhausted tumor-resident T cells. Contrary to the assumption that IL-10 produces an immunosuppressive tumor microenvironment (TME), it promotes activation of tumor-resident CD8+ T cells, which aids tumor rejection. Emerging data from published early-Phase trials have shown mixed results in different tumor types. In this review, we summarize the biological effects of IL-10 and highlight the clinical experience using pegilodecakin.

Original language	English (US)
Pages (from-to)	716-725
Number of pages	10
Journal	Trends in Cancer
Volume	9
Issue number	9
DOIs	https://doi.org/10.1016/j.trecan.2023.05.003
State	Published - Sep 2023

Keywords

cancer
inflammation
interleukin 10
pegilodecakin
pegylated IL-10
T cell

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.trecan.2023.05.003

Cite this

@article{6d0b879872fa49a397e2e081195a6e91,

title = "Interleukin-10 in cancer immunotherapy: from bench to bedside",

abstract = "Interleukin (IL)-10 was one of the first cytokines to be recognized. However, its functionality in promoting antitumor immunity was described more recently. Context- and concentration-dependent biological effects are the hallmarks of the pleiotropic role of IL-10. Despite reducing tumor-promoting inflammation, IL-10 may have a role in rejuvenating exhausted tumor-resident T cells. Contrary to the assumption that IL-10 produces an immunosuppressive tumor microenvironment (TME), it promotes activation of tumor-resident CD8+ T cells, which aids tumor rejection. Emerging data from published early-Phase trials have shown mixed results in different tumor types. In this review, we summarize the biological effects of IL-10 and highlight the clinical experience using pegilodecakin.",

keywords = "cancer, inflammation, interleukin 10, pegilodecakin, pegylated IL-10, T cell",

author = "Salkeni, {Mohamad Adham} and Aung Naing",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = sep,

doi = "10.1016/j.trecan.2023.05.003",

language = "English (US)",

volume = "9",

pages = "716--725",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "9",

}

TY - JOUR

T1 - Interleukin-10 in cancer immunotherapy

T2 - from bench to bedside

AU - Salkeni, Mohamad Adham

AU - Naing, Aung

PY - 2023/9

Y1 - 2023/9

N2 - Interleukin (IL)-10 was one of the first cytokines to be recognized. However, its functionality in promoting antitumor immunity was described more recently. Context- and concentration-dependent biological effects are the hallmarks of the pleiotropic role of IL-10. Despite reducing tumor-promoting inflammation, IL-10 may have a role in rejuvenating exhausted tumor-resident T cells. Contrary to the assumption that IL-10 produces an immunosuppressive tumor microenvironment (TME), it promotes activation of tumor-resident CD8+ T cells, which aids tumor rejection. Emerging data from published early-Phase trials have shown mixed results in different tumor types. In this review, we summarize the biological effects of IL-10 and highlight the clinical experience using pegilodecakin.

AB - Interleukin (IL)-10 was one of the first cytokines to be recognized. However, its functionality in promoting antitumor immunity was described more recently. Context- and concentration-dependent biological effects are the hallmarks of the pleiotropic role of IL-10. Despite reducing tumor-promoting inflammation, IL-10 may have a role in rejuvenating exhausted tumor-resident T cells. Contrary to the assumption that IL-10 produces an immunosuppressive tumor microenvironment (TME), it promotes activation of tumor-resident CD8+ T cells, which aids tumor rejection. Emerging data from published early-Phase trials have shown mixed results in different tumor types. In this review, we summarize the biological effects of IL-10 and highlight the clinical experience using pegilodecakin.

KW - cancer

KW - inflammation

KW - interleukin 10

KW - pegilodecakin

KW - pegylated IL-10

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=85162918493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85162918493&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2023.05.003

DO - 10.1016/j.trecan.2023.05.003

M3 - Review article

C2 - 37321942

AN - SCOPUS:85162918493

SN - 2405-8033

VL - 9

SP - 716

EP - 725

JO - Trends in Cancer

JF - Trends in Cancer

IS - 9

ER -

Interleukin-10 in cancer immunotherapy: from bench to bedside

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this